ArticleFrontiers in endocrinology2022
Global, Regional and National Burden of Cancers Attributable to High Fasting Plasma Glucose in 204 Countries and Territories, 1990-2019.
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Observational
- Global burden of cancers attributable to high fasting plasma glucose from 1990 to 2021 and projections until 2031.Diabetology & metabolic syndrome · 2026Article
- Global Patterns and Trends in Lifetime Risks of Developing and Dying from Cancer, 1990-2021.Health data science · 2026Article
- Global burden of disease attributable to high fasting plasma glucose from 1990 to 2021: a spatiotemporal analysis of global burden of disease 2021.Frontiers in cardiovascular medicine · 2026Article
- Global burden of 13 non-communicable diseases attributable to high fasting plasma glucose from the GBD 2021 study.Nutrition & diabetes · 2025Article
- Comparative study of early onset cancer burden between China and the United States from 1990 to 2021.Scientific reports · 2025Article
- Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States.Clinical and molecular hepatology · 2025Article
- Global Burden of Tracheal, Bronchus, and Lung Cancer in Adults Over 55 Years Old Based on Socio demographic Status and Geographical and Gender Differences from 2010-2021.Thoracic research and practice · 2025Article
- Global burden of colorectal cancer attributable to metabolic risks from 1990 to 2021, with projections of mortality to 2035.International journal of colorectal disease · 2025Article
- Global burden of colorectal cancer attributable to metabolic risks from 1990 to 2021, with predictions to 2046.BMC cancer · 2025Article
- Trends and projection of burden on lung cancer and risk factors in China from 1990 to 2060.Thoracic cancer · 2024Article
- Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019.The journal of nutrition, health & aging · 2024Article
- Cancer burden attributable to risk factors, 1990-2019: A comparative risk assessment.iScience · 2024Article
- Global and regional estimates of tuberculosis burden attributed to high fasting plasma glucose from 1990 to 2019: emphasis on earlier glycemic control.BMC public health · 2024Article
- Global, regional, and national burden of tracheal, bronchus, and lung cancers attributable to high fasting plasma glucose: A systematic analysis of global burden of disease 2019.Journal of diabetes · 2024Article
- Global burden of pancreatic cancer attributable to metabolic risks from 1990 to 2019, with projections of mortality to 2030.BMC public health · 2024Article
- Trend and forecast analysis of the changing disease burden of pancreatic cancer attributable to high fasting glucose in China, 1990-2021.Frontiers in oncology · 2024Article
- Pancreatic cancer mortality trends attributable to high fasting blood sugar over the period 1990-2019 and projections up to 2040.Frontiers in endocrinology · 2024Article
- Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019.Cancer medicine · 2023Article
- Global, regional, and national time trends in cancer mortality attributable to high fasting plasma glucose: an age-period cohort analysis.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 5 countries.
Funding
Abstract
Background: To report the burden of cancers attributable to high fasting plasma glucose (HFPG) by sex, age, location, cancer type and Socio-demographic Index (SDI) over the period 1990 to 2019 for 204 countries and territories. Methods: Using the Comparative Risk Assessment approach of Global Burden of Disease (GBD) study 2019, the burden of cancers attributable to HFPG was reported in 1990 and 2019. Results: Globally, in 2019 there were an estimated 419.3 thousand cancer deaths (95% UI: 115.7 to 848.5) and 8.6 million cancer DALYs (2.4 to 17.6) attributable to HFPG. By sex, 4.6 (1.1 to 9.9) and 4.0 (1.1 to 8.4) million global cancer DALYs were attributable to HFPG in men and women, respectively. The global age-standardized death and DALY rates of cancers attributable to HFPG (per 100,000) have increased by 27.8% (20.5 to 38.7%) and 24.5% (16.4 to 35.6%), respectively, since 1990. High-income North America (9.5 [2.7 to 18.8]) and Eastern Sub-Saharan Africa (2.0 [0.5 to 4.2]) had the highest and lowest regional age-standardized death rates, respectively, for cancers attributable to HFPG. In 2019, the global number of attributable cancer DALYs were highest in 65-69 age group. Moreover, there was an overall positive association between SDI and the regional age-standardized DALY rate for HFPG-attributable cancers. Conclusions: HFPG was associated with more burden in 2019. Preventive programs for diabetes and screening of individuals with diabetes for cancers, especially in older males living in developed countries, are required to arrest the large increases in HFPG-attributable cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.